| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $20.7M | -5.3% |
| SG&A Expense | $15.4M | +45.0% |
| Operating Income | -$36.6M | -12.7% |
| Pre-tax Income | -$35.5M | -12.7% |
| Net Income | -$35.5M | -12.7% |
| EPS (Basic) | -$12.17 | -1117.0% |
| EPS (Diluted) | -$12.17 | -1117.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $22.2M | -40.1% |
| Short-term Investments | $36.1M | — |
| Current Assets | $61.3M | +60.1% |
| Total Assets | $61.6M | +57.9% |
| Current Liabilities | $9.1M | +147.7% |
| Stockholders' Equity | $52.5M | +48.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$30.7M | -7.1% |
| Capital Expenditures | $37K | -58.0% |
| Investing Cash Flow | -$36.0M | — |
| Financing Cash Flow | $51.9M | +110.1% |
| Free Cash Flow | -$30.8M | -6.9% |